Investing Ideas
/
Polish Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Polish Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

1 new

Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.

1 companies

Selvita

Market Cap: zł568.1m

Provides drug discovery, drug development, and contract testing services in Poland.

New

SLV

zł30.95

1.5%

-1.7%